TY - JOUR AU - Papaemmanuil, E. AU - Gerstung, M. AU - Bullinger, L. AU - Gaidzik, V. I. AU - Paschka, P. AU - Roberts, N. D. PY - 2016 DA - 2016// TI - Genomic classification and prognosis in acute myeloid leukemia JO - N Engl J Med VL - 374 UR - https://doi.org/10.1056/NEJMoa1516192 DO - 10.1056/NEJMoa1516192 ID - Papaemmanuil2016 ER - TY - JOUR AU - Patel, J. P. AU - Gonen, M. AU - Figueroa, M. E. AU - Fernandez, H. AU - Sun, Z. AU - Racevskis, J. PY - 2012 DA - 2012// TI - Prognostic relevance of integrated genetic profiling in acute myeloid leukemia JO - N Engl J Med VL - 366 UR - https://doi.org/10.1056/NEJMoa1112304 DO - 10.1056/NEJMoa1112304 ID - Patel2012 ER - TY - JOUR AU - Grimwade, D. AU - Hills, R. K. AU - Moorman, A. V. AU - Walker, H. AU - Chatters, S. AU - Goldstone, A. H. PY - 2010 DA - 2010// TI - Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials JO - Blood VL - 116 UR - https://doi.org/10.1182/blood-2009-11-254441 DO - 10.1182/blood-2009-11-254441 ID - Grimwade2010 ER - TY - JOUR AU - Grimwade, D. AU - Mrozek, K. PY - 2011 DA - 2011// TI - Diagnostic and prognostic value of cytogenetics in acute myeloid leukemia JO - Hematol Oncol Clin North Am VL - 25 UR - https://doi.org/10.1016/j.hoc.2011.09.018 DO - 10.1016/j.hoc.2011.09.018 ID - Grimwade2011 ER - TY - JOUR AU - Lichtenegger, F. S. AU - Krupka, C. AU - Haubner, S. AU - Kohnke, T. AU - Subklewe, M. PY - 2017 DA - 2017// TI - Recent developments in immunotherapy of acute myeloid leukemia JO - J Hematol Oncol VL - 10 UR - https://doi.org/10.1186/s13045-017-0505-0 DO - 10.1186/s13045-017-0505-0 ID - Lichtenegger2017 ER - TY - JOUR AU - Grimwade, D. AU - Ivey, A. AU - Huntly, B. J. PY - 2016 DA - 2016// TI - Molecular landscape of acute myeloid leukemia in younger adults and its clinical relevance JO - Blood VL - 127 UR - https://doi.org/10.1182/blood-2015-07-604496 DO - 10.1182/blood-2015-07-604496 ID - Grimwade2016 ER - TY - JOUR AU - Liu, B. AU - Song, Y. AU - Liu, D. PY - 2017 DA - 2017// TI - Clinical trials of CAR-T cells in China JO - J Hematol Oncol VL - 10 UR - https://doi.org/10.1186/s13045-017-0535-7 DO - 10.1186/s13045-017-0535-7 ID - Liu2017 ER - TY - STD TI - DiNardo DC, JE C. In: Tallman MS, McCrae KR, Sonali S, Crowther MA, editors. Mutations in AML: prognostic and therapeutic implications: Hematology, Washington: American Society of Hematology. 2016. p. 348–55. ID - ref8 ER - TY - JOUR AU - Schnittger, S. AU - Schoch, C. AU - Kern, W. AU - Mecucci, C. AU - Tschulik, C. AU - Martelli, M. F. PY - 2005 DA - 2005// TI - Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype JO - Blood VL - 106 UR - https://doi.org/10.1182/blood-2005-06-2248 DO - 10.1182/blood-2005-06-2248 ID - Schnittger2005 ER - TY - JOUR AU - Pratcorona, M. AU - Brunet, S. AU - Nomdedeu, J. AU - Ribera, J. M. AU - Tormo, M. AU - Duarte, R. PY - 2013 DA - 2013// TI - Favorable outcome of patients with acute myeloid leukemia harboring a low-allelic burden FLT3-ITD mutation and concomitant NPM1 mutation: relevance to post-remission therapy JO - Blood VL - 121 UR - https://doi.org/10.1182/blood-2012-06-431122 DO - 10.1182/blood-2012-06-431122 ID - Pratcorona2013 ER - TY - JOUR AU - Haferlach, C. AU - Mecucci, C. AU - Schnittger, S. AU - Kohlmann, A. AU - Mancini, M. AU - Cuneo, A. PY - 2009 DA - 2009// TI - AML with mutated NPM1 carrying a normal or aberrant karyotype show overlapping biologic, pathologic, immunophenotypic, and prognostic features JO - Blood VL - 114 UR - https://doi.org/10.1182/blood-2009-01-197871 DO - 10.1182/blood-2009-01-197871 ID - Haferlach2009 ER - TY - JOUR AU - Versluis, J. AU - In ‘t Hout, F. E. AU - Devillier, R. AU - van Putten, W. L. AU - Manz, M. G. AU - Vekemans, M. C. PY - 2017 DA - 2017// TI - Comparative value of post-remission treatment in cytogenetically normal AML subclassified by NPM1 and FLT3-ITD allelic ratio JO - Leukemia VL - 31 UR - https://doi.org/10.1038/leu.2016.183 DO - 10.1038/leu.2016.183 ID - Versluis2017 ER - TY - JOUR AU - Döhner, H. AU - Estey, E. AU - Grimwade, D. AU - Amadori, S. AU - Appelbaum, F. R. AU - Büchner, T. PY - 2017 DA - 2017// TI - Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel JO - Blood VL - 129 UR - https://doi.org/10.1182/blood-2016-08-733196 DO - 10.1182/blood-2016-08-733196 ID - Döhner2017 ER - TY - STD TI - O’ Donnell MR. Tallman MS. Abboud CN. Altman JK. Appelbaum FR. Bhatt VR, et al. NCCN clinical practice Guilelines in oncology: acute meyloid leukemia. Version 2. 2018. https://www.nccn.org/professionals/physician_gls/default.aspx#site. Accessed 1 Aug 2018. UR - https://www.nccn.org/professionals/physician_gls/default.aspx#site ID - ref14 ER - TY - JOUR AU - Loghavi, S. AU - Zuo, Z. AU - Ravandi, F. AU - Kantarjian, H. M. AU - Bueso-Ramos, C. AU - Zhang, L. PY - 2014 DA - 2014// TI - Clinical features of de novo acute myeloid leukemia with concurrent DNMT3A, FLT3 and NPM1 mutations JO - J Hematol Oncol VL - 7 UR - https://doi.org/10.1186/s13045-014-0074-4 DO - 10.1186/s13045-014-0074-4 ID - Loghavi2014 ER - TY - JOUR AU - Patel, S. S. AU - Kuo, F. C. AU - Gibson, C. J. AU - Steensma, D. P. AU - Soiffer, R. J. AU - Alyea, E. P. PY - 2018 DA - 2018// TI - High NPM1-mutant allele burden at diagnosis predicts unfavorable outcomes in de novo AML JO - Blood VL - 131 UR - https://doi.org/10.1182/blood-2018-01-828467 DO - 10.1182/blood-2018-01-828467 ID - Patel2018 ER - TY - JOUR AU - Becker, H. AU - Marcucci, G. AU - Maharry, K. AU - Radmacher, M. D. AU - Mrozek, K. AU - Margeson, D. PY - 2010 DA - 2010// TI - Favorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene- and microRNA-expression signatures: a Cancer and leukemia group B study JO - J Clin Oncol VL - 28 UR - https://doi.org/10.1200/JCO.2009.25.1496 DO - 10.1200/JCO.2009.25.1496 ID - Becker2010 ER - TY - JOUR AU - Ostronoff, F. AU - Othus, M. AU - Lazenby, M. AU - Estey, E. AU - Appelbaum, F. R. AU - Evans, A. PY - 2015 DA - 2015// TI - Prognostic significance of NPM1 mutations in the absence of FLT3-internal tandem duplication in older patients with acute myeloid leukemia: a SWOG and UK National Cancer Research Institute/Medical Research Council report JO - J Clin Oncol VL - 33 UR - https://doi.org/10.1200/JCO.2014.58.0571 DO - 10.1200/JCO.2014.58.0571 ID - Ostronoff2015 ER - TY - JOUR AU - Lazenby, M. AU - Gilkes, A. F. AU - Marrin, C. AU - Evans, A. AU - Hills, R. K. AU - Burnett, A. K. PY - 2014 DA - 2014// TI - The prognostic relevance of flt3 and npm1 mutations on older patients treated intensively or non-intensively: a study of 1312 patients in the UK NCRI AML16 trial JO - Leukemia VL - 28 UR - https://doi.org/10.1038/leu.2014.90 DO - 10.1038/leu.2014.90 ID - Lazenby2014 ER - TY - JOUR AU - Luskin, M. R. AU - Lee, J. W. AU - Fernandez, H. F. AU - Abdel-Wahab, O. AU - Bennett, J. M. AU - Ketterling, R. P. PY - 2016 DA - 2016// TI - Benefit of high-dose daunorubicin in AML induction extends across cytogenetic and molecular groups JO - Blood VL - 127 UR - https://doi.org/10.1182/blood-2015-07-657403 DO - 10.1182/blood-2015-07-657403 ID - Luskin2016 ER - TY - JOUR AU - Schlenk, R. F. AU - Frohling, S. AU - Hartmann, F. AU - Fischer, J. T. AU - Glasmacher, A. AU - del Valle, F. PY - 2004 DA - 2004// TI - Phase III study of all-trans retinoic acid in previously untreated patients 61 years or older with acute myeloid leukemia JO - Leukemia VL - 18 UR - https://doi.org/10.1038/sj.leu.2403528 DO - 10.1038/sj.leu.2403528 ID - Schlenk2004 ER - TY - JOUR AU - El Hajj, H. AU - Dassouki, Z. AU - Berthier, C. AU - Raffoux, E. AU - Ades, L. AU - Legrand, O. PY - 2015 DA - 2015// TI - Retinoic acid and arsenic trioxide trigger degradation of mutated NPM1, resulting in apoptosis of AML cells JO - Blood VL - 125 UR - https://doi.org/10.1182/blood-2014-11-612416 DO - 10.1182/blood-2014-11-612416 ID - El Hajj2015 ER - TY - JOUR AU - Schlenk, R. F. AU - Kayser, S. AU - Bullinger, L. AU - Kobbe, G. AU - Casper, J. AU - Ringhoffer, M. PY - 2014 DA - 2014// TI - Differential impact of allelic ratio and insertion site in FLT3-ITD-positive AML with respect to allogeneic transplantation JO - Blood VL - 124 UR - https://doi.org/10.1182/blood-2014-05-578070 DO - 10.1182/blood-2014-05-578070 ID - Schlenk2014 ER - TY - JOUR AU - Wang, Y. AU - Xu, Y. AU - Li, S. AU - Liu, J. AU - Xing, Y. AU - Xing, H. PY - 2018 DA - 2018// TI - Targeting FLT3 in acute myeloid leukemia using ligand-based chimeric antigen receptor-engineered T cells JO - J Hematol Oncol VL - 11 UR - https://doi.org/10.1186/s13045-018-0603-7 DO - 10.1186/s13045-018-0603-7 ID - Wang2018 ER - TY - JOUR AU - Rollig, C. AU - Serve, H. AU - Huttmann, A. AU - Noppeney, R. AU - Muller-Tidow, C. AU - Krug, U. PY - 2015 DA - 2015// TI - Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial JO - Lancet Oncol VL - 16 UR - https://doi.org/10.1016/S1470-2045(15)00362-9 DO - 10.1016/S1470-2045(15)00362-9 ID - Rollig2015 ER - TY - JOUR AU - Stone, R. M. AU - Mandrekar, S. J. AU - Sanford, B. L. AU - Laumann, K. AU - Geyer, S. AU - Bloomfield, C. D. PY - 2017 DA - 2017// TI - Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation JO - N Engl J Med VL - 377 UR - https://doi.org/10.1056/NEJMoa1614359 DO - 10.1056/NEJMoa1614359 ID - Stone2017 ER - TY - JOUR AU - Cortes, J. E. AU - Kantarjian, H. AU - Foran, J. M. AU - Ghirdaladze, D. AU - Zodelava, M. AU - Borthakur, G. PY - 2013 DA - 2013// TI - Phase I study of quizartinib administered daily to patients with relapsed or refractory acute myeloid leukemia irrespective of FMS-like tyrosine kinase 3-internal tandem duplication status JO - J Clin Oncol VL - 31 UR - https://doi.org/10.1200/JCO.2013.48.8783 DO - 10.1200/JCO.2013.48.8783 ID - Cortes2013 ER - TY - JOUR AU - Perl, A. E. AU - Altman, J. K. AU - Cortes, J. AU - Smith, C. AU - Litzow, M. AU - Baer, M. R. PY - 2017 DA - 2017// TI - Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study JO - Lancet Oncol VL - 18 UR - https://doi.org/10.1016/S1470-2045(17)30416-3 DO - 10.1016/S1470-2045(17)30416-3 ID - Perl2017 ER - TY - JOUR AU - Yang, X. AU - Wang, J. PY - 2018 DA - 2018// TI - Precision therapy for acute myeloid leukemia JO - J Hematol Oncol VL - 11 UR - https://doi.org/10.1186/s13045-017-0543-7 DO - 10.1186/s13045-017-0543-7 ID - Yang2018 ER - TY - STD TI - Cortes J, Khaled S, Martinelli G, Perl AE, Ganguly S, Russell N, et al. Quizartinib significantly prolongs overall survival in patients with FLT3-internal tandem duplication-mutated (Mut) relapsed/refractory AML in the phase 3, randomized, controlled quantum-r trial. European Hematology Association Congress Abstract. 2018:LB2600. https://learningcenter.ehaweb.org/eha/2018/stockholm/218882/jorge.cortes.quizartinib.significantly. prolongs.overall.survival.in.patients.htmlf=menu=6*ce_id=1346*ot_id=19045*media=3*browseby=8. Accessed 16 July 2018.  UR - https://learningcenter.ehaweb.org/eha/2018/stockholm/218882/jorge.cortes.quizartinib.significantly.prolongs.overall.survival.in.patients.htmlf=menu=6*ce_id=1346*ot_id=19045*media=3*browseby=8 ID - ref30 ER - TY - STD TI - Pratz K, Cherry M, Altman JK, Cooper BW, Cruz JC, Jurcic JG, et al. Preliminary results from a phase 1 study of gilteritinib in combination with induction and consolidation chemotherapy in subjects with newly diagnosed acute myeloid leukemia (AML). Blood. 2017;130:722. ID - ref31 ER - TY - STD TI - Walter RB, Collins RH, Stone RM, Tallman MS, Karanes C, Vigil CE, et al. Addition of crenolanib to standard induction and consolidation therapies improved long-term outcomes in newly diagnosed FLT3 mutant AML patients ≤ 60 years old. European Hematology Association Congress Abstract. 2018:PF227. https://learningcenter.ehaweb.org/eha/2018/stockholm/214713/roland.b.walter.addition.of.crenolanib.to.standard.induction.and.consolidation.html?f=menu=6*ce_id=1346*ot_id=19045*media=3*browseby=8. Accessed 16 July 2018. UR - https://learningcenter.ehaweb.org/eha/2018/stockholm/214713/roland.b.walter.addition.of.crenolanib.to.standard.induction.and.consolidation.html?f=menu=6*ce_id=1346*ot_id=19045*media=3*browseby=8 ID - ref32 ER - TY - JOUR AU - Saygin, C. AU - Carraway, H. E. PY - 2017 DA - 2017// TI - Emerging therapies for acute myeloid leukemia JO - J Hematol Oncol VL - 10 UR - https://doi.org/10.1186/s13045-017-0463-6 DO - 10.1186/s13045-017-0463-6 ID - Saygin2017 ER - TY - JOUR AU - Wei, H. AU - Wang, Y. AU - Zhou, C. AU - Lin, D. AU - Liu, B. AU - Liu, K. PY - 2018 DA - 2018// TI - Distinct genetic alteration profiles of acute myeloid leukemia between Caucasian and eastern Asian population JO - J Hematol Oncol VL - 11 UR - https://doi.org/10.1186/s13045-018-0566-8 DO - 10.1186/s13045-018-0566-8 ID - Wei2018 ER - TY - JOUR AU - Qin, Y. Z. AU - Wang, Y. AU - Xu, L. P. AU - Zhang, X. H. AU - Chen, H. AU - Han, W. PY - 2017 DA - 2017// TI - The dynamics of RUNX1-RUNX1T1 transcript levels after allogeneic hematopoietic stem cell transplantation predict relapse in patients with t (8;21) acute myeloid leukemia JO - J Hematol Oncol VL - 10 UR - https://doi.org/10.1186/s13045-017-0414-2 DO - 10.1186/s13045-017-0414-2 ID - Qin2017 ER - TY - JOUR AU - Paschka, P. AU - Marcucci, G. AU - Ruppert, A. S. AU - Mrozek, K. AU - Chen, H. AU - Kittles, R. A. PY - 2006 DA - 2006// TI - Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv (16) and t (8;21): a Cancer and leukemia group B study JO - J Clin Oncol VL - 24 UR - https://doi.org/10.1200/JCO.2006.06.9500 DO - 10.1200/JCO.2006.06.9500 ID - Paschka2006 ER - TY - JOUR AU - Gong, B. F. AU - Tan, Y. H. AU - Liao, A. J. AU - Li, J. AU - Mao, Y. Y. AU - Lu, N. PY - 2018 DA - 2018// TI - Impact of KIT D816 mutation on salvage therapy in relapsed acute myeloid leukemia with t (8;21) translocation JO - Zhonghua Xue Ye Xue Za Zhi VL - 39 UR - https://doi.org/10.3760/cma.j.issn.0253-2727.2018.06.004 DO - 10.3760/cma.j.issn.0253-2727.2018.06.004 ID - Gong2018 ER - TY - JOUR AU - Miyawaki, S. AU - Ohtake, S. AU - Fujisawa, S. AU - Kiyoi, H. AU - Shinagawa, K. AU - Usui, N. PY - 2011 DA - 2011// TI - A randomized comparison of 4 courses of standard-dose multiagent chemotherapy versus 3 courses of high-dose cytarabine alone in postremission therapy for acute myeloid leukemia in adults: the JALSG AML201 study JO - Blood VL - 117 UR - https://doi.org/10.1182/blood-2010-07-295279 DO - 10.1182/blood-2010-07-295279 ID - Miyawaki2011 ER - TY - JOUR AU - Marcucci, G. AU - Geyer, S. AU - Zhao, W. AU - Caroll, A. J. AU - Bucci, D. AU - Uy, G. L. PY - 2014 DA - 2014// TI - Adding KIT inhibitor Dasatinib (DAS) to chemotherapy overcomes the negative impact of KIT mutation/over-expression in core binding factor (CBF) acute myeloid leukemia (AML): results from CALGB 10801(Alliance) JO - Blood VL - 124 ID - Marcucci2014 ER - TY - JOUR AU - Gaidzik, V. I. AU - Teleanu, V. AU - Papaemmanuil, E. AU - Weber, D. AU - Paschka, P. AU - Hahn, J. PY - 2016 DA - 2016// TI - RUNX1 mutations in acute myeloid leukemia are associated with distinct clinico-pathologic and genetic features JO - Leukemia VL - 30 UR - https://doi.org/10.1038/leu.2016.126 DO - 10.1038/leu.2016.126 ID - Gaidzik2016 ER - TY - JOUR AU - Gaidzik, V. I. AU - Bullinger, L. AU - Schlenk, R. F. AU - Zimmermann, A. S. AU - Rock, J. AU - Paschka, P. PY - 2011 DA - 2011// TI - RUNX1 mutations in acute myeloid leukemia: results from a comprehensive genetic and clinical analysis from the AML study group JO - J Clin Oncol VL - 29 UR - https://doi.org/10.1200/JCO.2010.30.7926 DO - 10.1200/JCO.2010.30.7926 ID - Gaidzik2011 ER - TY - JOUR AU - Arber, D. A. AU - Orazi, A. AU - Hasserjian, R. AU - Thiele, J. AU - Borowitz, M. J. AU - Le Beau, M. M. PY - 2016 DA - 2016// TI - The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia JO - Blood VL - 127 UR - https://doi.org/10.1182/blood-2016-03-643544 DO - 10.1182/blood-2016-03-643544 ID - Arber2016 ER - TY - JOUR AU - Stengel, A. AU - Kern, W. AU - Meggendorfer, M. AU - Nadarajah, N. AU - Perglerova, K. AU - Haferlach, T. PY - 2018 DA - 2018// TI - Number of RUNX1 mutations, wild-type allele loss and additional mutations impact on prognosis in adult RUNX1-mutated AML JO - Leukemia VL - 32 UR - https://doi.org/10.1038/leu.2017.239 DO - 10.1038/leu.2017.239 ID - Stengel2018 ER - TY - JOUR AU - Taskesen, E. AU - Bullinger, L. AU - Corbacioglu, A. AU - Sanders, M. A. AU - Erpelinck, C. A. AU - Wouters, B. J. PY - 2011 DA - 2011// TI - Prognostic impact, concurrent genetic mutations, and gene expression features of AML with CEBPA mutations in a cohort of 1182 cytogenetically normal AML patients: further evidence for CEBPA double mutant AML as a distinctive disease entity JO - Blood VL - 117 UR - https://doi.org/10.1182/blood-2010-09-307280 DO - 10.1182/blood-2010-09-307280 ID - Taskesen2011 ER - TY - JOUR AU - Wouters, B. J. AU - Lowenberg, B. AU - Erpelinck-Verschueren, C. A. AU - van Putten, W. L. AU - Valk, P. J. AU - Delwel, R. PY - 2009 DA - 2009// TI - Double CEBPA mutations, but not single CEBPA mutations, define a subgroup of acute myeloid leukemia with a distinctive gene expression profile that is uniquely associated with a favorable outcome JO - Blood VL - 113 UR - https://doi.org/10.1182/blood-2008-09-179895 DO - 10.1182/blood-2008-09-179895 ID - Wouters2009 ER - TY - JOUR AU - Schlenk, R. F. AU - Taskesen, E. AU - van Norden, Y. AU - Krauter, J. AU - Ganser, A. AU - Bullinger, L. PY - 2013 DA - 2013// TI - The value of allogeneic and autologous hematopoietic stem cell transplantation in prognostically favorable acute myeloid leukemia with double mutant CEBPA JO - Blood VL - 122 UR - https://doi.org/10.1182/blood-2013-05-503847 DO - 10.1182/blood-2013-05-503847 ID - Schlenk2013 ER - TY - JOUR AU - Dang, L. AU - White, D. W. AU - Gross, S. AU - Bennett, B. D. AU - Bittinger, M. A. AU - Driggers, E. M. PY - 2009 DA - 2009// TI - Cancer-associated IDH1 mutations produce 2-hydroxyglutarate JO - Nature VL - 462 UR - https://doi.org/10.1038/nature08617 DO - 10.1038/nature08617 ID - Dang2009 ER - TY - JOUR AU - Figueroa, M. E. AU - Abdel-Wahab, O. AU - Lu, C. AU - Ward, P. S. AU - Patel, J. AU - Shih, A. PY - 2010 DA - 2010// TI - Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation JO - Cancer Cell VL - 18 UR - https://doi.org/10.1016/j.ccr.2010.11.015 DO - 10.1016/j.ccr.2010.11.015 ID - Figueroa2010 ER - TY - JOUR AU - Hackl, H. AU - Astanina, K. AU - Wieser, R. PY - 2017 DA - 2017// TI - Molecular and genetic alterations associated with therapy resistance and relapse of acute myeloid leukemia JO - J Hematol Oncol VL - 10 UR - https://doi.org/10.1186/s13045-017-0416-0 DO - 10.1186/s13045-017-0416-0 ID - Hackl2017 ER - TY - JOUR AU - Abbas, S. AU - Lugthart, S. AU - Kavelaars, F. G. AU - Schelen, A. AU - Koenders, J. E. AU - Zeilemaker, A. PY - 2010 DA - 2010// TI - Acquired mutations in the genes encoding IDH1 and IDH2 both are recurrent aberrations in acute myeloid leukemia: prevalence and prognostic value JO - Blood VL - 116 UR - https://doi.org/10.1182/blood-2009-11-250878 DO - 10.1182/blood-2009-11-250878 ID - Abbas2010 ER - TY - JOUR AU - Marcucci, G. AU - Maharry, K. AU - Wu, Y. Z. AU - Radmacher, M. D. AU - Mrozek, K. AU - Margeson, D. PY - 2010 DA - 2010// TI - IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and leukemia group B study JO - J Clin Oncol VL - 28 UR - https://doi.org/10.1200/JCO.2009.27.3730 DO - 10.1200/JCO.2009.27.3730 ID - Marcucci2010 ER - TY - JOUR AU - Green, C. L. AU - Evans, C. M. AU - Zhao, L. AU - Hills, R. K. AU - Burnett, A. K. AU - Linch, D. C. PY - 2011 DA - 2011// TI - The prognostic significance of IDH2 mutations in AML depends on the location of the mutation JO - Blood VL - 118 UR - https://doi.org/10.1182/blood-2010-12-322479 DO - 10.1182/blood-2010-12-322479 ID - Green2011 ER - TY - JOUR AU - Boissel, N. AU - Nibourel, O. AU - Renneville, A. AU - Gardin, C. AU - Reman, O. AU - Contentin, N. PY - 2010 DA - 2010// TI - Prognostic impact of isocitrate dehydrogenase enzyme isoforms 1 and 2 mutations in acute myeloid leukemia: a study by the acute leukemia French association group JO - J Clin Oncol VL - 28 UR - https://doi.org/10.1200/JCO.2010.28.2285 DO - 10.1200/JCO.2010.28.2285 ID - Boissel2010 ER - TY - JOUR AU - Stein, E. M. AU - DiNardo, C. D. AU - Pollyea, D. A. AU - Fathi, A. T. AU - Roboz, G. J. AU - Altman, J. K. PY - 2017 DA - 2017// TI - Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia JO - Blood VL - 130 UR - https://doi.org/10.1182/blood-2017-04-779405 DO - 10.1182/blood-2017-04-779405 ID - Stein2017 ER - TY - STD TI - Pollyea DA, DiNardo CD, Botton SD, Stein EM, Roboz GJ, Mims AS, et al. Ivosidenib (AG-120) in mutant IDH1 relapsed/refractory Acute myeloid leukemia:results of a phase 1 study. European Hematology Association Congress Abstract. 2018:S1560. https://learningcenter.ehaweb.org/eha/2018/stockholm/214479/daniel.a.pollyea.ivosidenib.28ag-12029.in.mutant.idh1.relapsed.refractory.acute.html?f=menu=6*ce_id=1346 *ot_id=19045*media=3*browseby=8. Accessed 16 July 2018. UR - https://learningcenter.ehaweb.org/eha/2018/stockholm/214479/daniel.a.pollyea.ivosidenib.28ag-12029.in.mutant.idh1.relapsed.refractory.acute.html?f=menu=6*ce_id=1346*ot_id=19045*media=3*browseby=8 ID - ref55 ER - TY - JOUR AU - Wei, A. AU - Strickland, S. A. AU - Roboz, G. J. AU - Hou, J. -. Z. AU - Fiedler, W. AU - Lin, T. L. PY - 2016 DA - 2016// TI - Safety and efficacy of venetoclax plus low-dose cytarabine in treatment-naive patients aged ≥65 years with acute myeloid leukemia JO - Blood VL - 128 ID - Wei2016 ER - TY - JOUR AU - Yuan, X. Q. AU - Peng, L. AU - Zeng, W. J. AU - Jiang, B. Y. AU - Li, G. C. AU - Chen, X. P. PY - 2016 DA - 2016// TI - DNMT3A R882 mutations predict a poor prognosis in AML: a meta-analysis from 4474 patients JO - Medicine VL - 95 UR - https://doi.org/10.1097/MD.0000000000003519 DO - 10.1097/MD.0000000000003519 ID - Yuan2016 ER - TY - JOUR AU - Gaidzik, V. I. AU - Schlenk, R. F. AU - Paschka, P. AU - Stolzle, A. AU - Spath, D. AU - Kuendgen, A. PY - 2013 DA - 2013// TI - Clinical impact of DNMT3A mutations in younger adult patients with acute myeloid leukemia: results of the AML study group (AMLSG) JO - Blood VL - 121 UR - https://doi.org/10.1182/blood-2012-10-461624 DO - 10.1182/blood-2012-10-461624 ID - Gaidzik2013 ER - TY - JOUR AU - Gale, R. E. AU - Lamb, K. AU - Allen, C. AU - El-Sharkawi, D. AU - Stowe, C. AU - Jenkinson, S. PY - 2015 DA - 2015// TI - Simpson’s paradox and the impact of different DNMT3A mutations on outcome in younger adults with acute myeloid leukemia JO - J Clin Oncol VL - 33 UR - https://doi.org/10.1200/JCO.2014.59.2022 DO - 10.1200/JCO.2014.59.2022 ID - Gale2015 ER - TY - JOUR AU - Micol, J. -. B. AU - Duployez, N. AU - Boissel, N. AU - Petit, A. AU - Geffroy, S. AU - Nibourel, O. AU - Lacombe, C. AU - Lapillonne, H. AU - Etancelin, P. AU - Figeac, M. AU - Renneville, A. AU - Castaigne, S. AU - Leverger, G. AU - Ifrah, N. AU - Dombret, H. AU - Preudhomme, C. AU - Abdel-Wahab, O. AU - Jourdan, E. PY - 2014 DA - 2014// TI - Frequent ASXL2 mutations in acute myeloid leukemia patients with t(8;21)/RUNX1-RUNX1T1 chromosomal translocations JO - Blood VL - 124 UR - https://doi.org/10.1182/blood-2014-04-571018 DO - 10.1182/blood-2014-04-571018 ID - Micol2014 ER - TY - JOUR AU - Shlush, L. I. AU - Zandi, S. AU - Mitchell, A. AU - Chen, W. C. AU - Brandwein, J. M. AU - Gupta, V. PY - 2014 DA - 2014// TI - Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia JO - Nature VL - 506 UR - https://doi.org/10.1038/nature13038 DO - 10.1038/nature13038 ID - Shlush2014 ER - TY - JOUR AU - Tan, Y. AU - Liu, H. AU - Chen, S. PY - 2015 DA - 2015// TI - Mutant DNA methylation regulators endow hematopoietic stem cells with the preleukemic stem cell property, a requisite of leukemia initiation and relapse JO - Front Med VL - 9 UR - https://doi.org/10.1007/s11684-015-0423-x DO - 10.1007/s11684-015-0423-x ID - Tan2015 ER - TY - JOUR AU - Jan, M. AU - Snyder, T. M. AU - Corces-Zimmerman, M. R. AU - Vyas, P. AU - Weissman, I. L. AU - Quake, S. R. PY - 2012 DA - 2012// TI - Clonal evolution of preleukemic hematopoietic stem cells precedes human acute myeloid leukemia JO - Sci Transl Med VL - 4 UR - https://doi.org/10.1126/scitranslmed.3004315 DO - 10.1126/scitranslmed.3004315 ID - Jan2012 ER - TY - JOUR AU - Hsu, Y. C. AU - Chiu, Y. C. AU - Lin, C. C. AU - Kuo, Y. Y. AU - Hou, H. A. AU - Tzeng, Y. S. PY - 2017 DA - 2017// TI - The distinct biological implications of Asxl1 mutation and its roles in leukemogenesis revealed by a knock-in mouse model JO - J Hematol Oncol VL - 10 UR - https://doi.org/10.1186/s13045-017-0508-x DO - 10.1186/s13045-017-0508-x ID - Hsu2017 ER - TY - JOUR AU - Jongen-Lavrencic, M. AU - Grob, T. AU - Hanekamp, D. AU - Kavelaars, F. G. AU - Al Hinai, A. AU - Zeilemaker, A. PY - 2018 DA - 2018// TI - Molecular Minimal Residual Disease in Acute Myeloid Leukemia JO - N Engl J Med VL - 378 UR - https://doi.org/10.1056/NEJMoa1716863 DO - 10.1056/NEJMoa1716863 ID - Jongen-Lavrencic2018 ER - TY - JOUR AU - Jongen-Lavrencic, M. AU - Tim Grob, F. G. AU - ASA, K. AU - Al Hinai, A. Z. AU - CAJ, E. -. V. AU - Yvette Norden, R. M. PY - 2017 DA - 2017// TI - Prospective mlecular MRD dtection by NGS: a powerful independent predictor for relapse and survival in adults with newly diagnosed AML JO - Blood VL - 130 UR - https://doi.org/10.1182/blood-2017-04-776385 DO - 10.1182/blood-2017-04-776385 ID - Jongen-Lavrencic2017 ER - TY - JOUR AU - Rothenberg-Thurley, M. AU - Amler, S. AU - Goerlich, D. AU - Kohnke, T. AU - Konstandin, N. P. AU - Schneider, S. PY - 2018 DA - 2018// TI - Persistence of pre-leukemic clones during first remission and risk of relapse in acute myeloid leukemia JO - Leukemia VL - 32 UR - https://doi.org/10.1038/s41375-018-0034-z DO - 10.1038/s41375-018-0034-z ID - Rothenberg-Thurley2018 ER - TY - JOUR AU - Lindsley, R. C. AU - Mar, B. G. AU - Mazzola, E. AU - Grauman, P. V. AU - Shareef, S. AU - Allen, S. L. PY - 2015 DA - 2015// TI - Acute myeloid leukemia ontogeny is defined by distinct somatic mutations JO - Blood VL - 125 UR - https://doi.org/10.1182/blood-2014-11-610543 DO - 10.1182/blood-2014-11-610543 ID - Lindsley2015 ER - TY - JOUR AU - Seiler, M. AU - Yoshimi, A. AU - Darman, R. AU - Chan, B. AU - Keaney, G. AU - Thomas, M. PY - 2018 DA - 2018// TI - H3B-8800, an orally available small-molecule splicing modulator, induces lethality in spliceosome-mutant cancers JO - Nat Med VL - 24 UR - https://doi.org/10.1038/nm.4493 DO - 10.1038/nm.4493 ID - Seiler2018 ER - TY - JOUR AU - Devillier, R. AU - Mansat-De Mas, V. AU - Gelsi-Boyer, V. AU - Demur, C. AU - Murati, A. AU - Corre, J. PY - 2015 DA - 2015// TI - Role of ASXL1 and TP53 mutations in the molecular classification and prognosis of acute myeloid leukemias with myelodysplasia-related changes JO - Oncotarget VL - 6 UR - https://doi.org/10.18632/oncotarget.3460 DO - 10.18632/oncotarget.3460 ID - Devillier2015 ER - TY - JOUR AU - Grossmann, V. AU - Schnittger, S. AU - Kohlmann, A. AU - Eder, C. AU - Roller, A. AU - Dicker, F. PY - 2012 DA - 2012// TI - A novel hierarchical prognostic model of AML solely based on molecular mutations JO - Blood VL - 120 UR - https://doi.org/10.1182/blood-2012-03-419622 DO - 10.1182/blood-2012-03-419622 ID - Grossmann2012 ER - TY - JOUR AU - Welch, J. S. AU - Petti, A. A. AU - Miller, C. A. AU - Fronick, C. C. AU - O'Laughlin, M. AU - Fulton, R. S. PY - 2016 DA - 2016// TI - TP53 and Decitabine in acute myeloid leukemia and myelodysplastic syndromes JO - N Engl J Med VL - 375 UR - https://doi.org/10.1056/NEJMoa1605949 DO - 10.1056/NEJMoa1605949 ID - Welch2016 ER - TY - JOUR AU - Andreeff, M. AU - Kelly, K. R. AU - Yee, K. AU - Assouline, S. AU - Strair, R. AU - Popplewell, L. PY - 2016 DA - 2016// TI - Results of the phase I trial of RG7112, a small-molecule MDM2 antagonist in leukemia JO - Clin Cancer Res VL - 22 UR - https://doi.org/10.1158/1078-0432.CCR-15-0481 DO - 10.1158/1078-0432.CCR-15-0481 ID - Andreeff2016 ER - TY - JOUR AU - Irish, J. M. AU - Anensen, N. AU - Hovland, R. AU - Skavland, J. AU - Borresen-Dale, A. L. AU - Bruserud, O. PY - 2007 DA - 2007// TI - Flt3 Y591 duplication and Bcl-2 overexpression are detected in acute myeloid leukemia cells with high levels of phosphorylated wild-type p53 JO - Blood VL - 109 UR - https://doi.org/10.1182/blood-2006-02-004234 DO - 10.1182/blood-2006-02-004234 ID - Irish2007 ER - TY - JOUR AU - Stilgenbauer, S. AU - Eichhorst, B. AU - Schetelig, J. AU - Coutre, S. AU - Seymour, J. F. AU - Munir, T. PY - 2016 DA - 2016// TI - Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study JO - Lancet Oncol VL - 17 UR - https://doi.org/10.1016/S1470-2045(16)30019-5 DO - 10.1016/S1470-2045(16)30019-5 ID - Stilgenbauer2016 ER - TY - STD TI - DiNardo CD, Pratz K, Potlur J, Pullarkat V, Jonas BA, Wei AH, et al. Durable response with venetoclax in combination with decitabine or azacitadine in elderly patients with acute myeloid leukemia. European Hematology Association Congress Abstract. 2018:S15630. https://learningcenter.ehaweb.org/eha/2018/stockholm/214482/courtney.d.dinardo.durable.response.with.venetoclax.in.combination.with.htmlf=menu=6*ce_id=1346*ot_id=19045*media=3*browseby=8. Accessed 16 July 2018. UR - https://learningcenter.ehaweb.org/eha/2018/stockholm/214482/courtney.d.dinardo.durable.response.with.venetoclax.in.combination.with.htmlf=menu=6*ce_id=1346*ot_id=19045*media=3*browseby=8 ID - ref76 ER - TY - JOUR AU - DiNardo, C. D. AU - Pratz, K. W. AU - Letai, A. AU - Jonas, B. A. AU - Wei, A. H. AU - Thirman, M. PY - 2018 DA - 2018// TI - Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study JO - Lancet Oncol VL - 19 UR - https://doi.org/10.1016/S1470-2045(18)30010-X DO - 10.1016/S1470-2045(18)30010-X ID - DiNardo2018 ER - TY - JOUR AU - Li, Y. AU - Xu, Q. AU - Lv, N. AU - Wang, L. AU - Zhao, H. AU - Wang, X. PY - 2017 DA - 2017// TI - Clinical implications of genome-wide DNA methylation studies in acute myeloid leukemia JO - J Hematol Oncol VL - 10 UR - https://doi.org/10.1186/s13045-017-0409-z DO - 10.1186/s13045-017-0409-z ID - Li2017 ER - TY - JOUR AU - Wei, S. AU - Wang, K. PY - 2016 DA - 2016// TI - Long noncoding RNAs: pivotal regulators in acute myeloid leukemia JO - Exp Hematol Oncol VL - 5 UR - https://doi.org/10.1186/s40164-016-0059-9 DO - 10.1186/s40164-016-0059-9 ID - Wei2016 ER - TY - JOUR AU - Zhang, C. AU - Liu, J. AU - Zhong, J. F. AU - Zhang, X. PY - 2017 DA - 2017// TI - Engineering CAR-T cells JO - Biomark Res VL - 5 UR - https://doi.org/10.1186/s40364-017-0102-y DO - 10.1186/s40364-017-0102-y ID - Zhang2017 ER - TY - JOUR AU - Park, J. H. AU - Riviere, I. AU - Gonen, M. AU - Wang, X. AU - Senechal, B. AU - Curran, K. J. PY - 2018 DA - 2018// TI - Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia JO - N Engl J Med VL - 378 UR - https://doi.org/10.1056/NEJMoa1709919 DO - 10.1056/NEJMoa1709919 ID - Park2018 ER - TY - JOUR AU - Ghelli Luserna di Rora, A. AU - Iacobucci, I. AU - Martinelli, G. PY - 2017 DA - 2017// TI - The cell cycle checkpoint inhibitors in the treatment of leukemias JO - J Hematol Oncol VL - 10 UR - https://doi.org/10.1186/s13045-017-0443-x DO - 10.1186/s13045-017-0443-x ID - Ghelli Luserna di Rora2017 ER - TY - JOUR AU - Gokbuget, N. AU - Dombret, H. AU - Bonifacio, M. AU - Reichle, A. AU - Graux, C. AU - Faul, C. PY - 2018 DA - 2018// TI - Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia JO - Blood VL - 131 UR - https://doi.org/10.1182/blood-2017-08-798322 DO - 10.1182/blood-2017-08-798322 ID - Gokbuget2018 ER - TY - JOUR AU - Fan, M. AU - Li, M. AU - Gao, L. AU - Geng, S. AU - Wang, J. AU - Wang, Y. PY - 2017 DA - 2017// TI - Chimeric antigen receptors for adoptive T cell therapy in acute myeloid leukemia JO - J Hematol Oncol VL - 10 UR - https://doi.org/10.1186/s13045-017-0519-7 DO - 10.1186/s13045-017-0519-7 ID - Fan2017 ER - TY - STD TI - Liu F, Pinz K, Ma Y, Wada M, Chen K, Ma G, et al. First in human CLL1-CD33 compound CAR T cells as a two-pronged approach for the treatment of refractory acute myeloid leukemia. European Hematology Association Congress Abstract. 2018:S149. https://learningcenter.ehaweb.org/eha/2018/stockholm/215925/fang.liu.first-in-huma n.cll1-cd33.compound.car.t.cells.as.a.two-pronged.html?f=menu=6*ce_id=1346*ot_id=19045*media=3*browseby=8. Accessed 16 July 2018. UR - https://learningcenter.ehaweb.org/eha/2018/stockholm/215925/fang.liu.first-in-human.cll1-cd33.compound.car.t.cells.as.a.two-pronged.html?f=menu=6*ce_id=1346*ot_id=19045*media=3*browseby=8 ID - ref85 ER -